My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

2.360 +0.030 (+1.29%)
Streaming Delayed Price Updated: 10:57 AM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 160,469
Open 2.360
Bid (Size) 2.340 (3)
Ask (Size) 2.370 (1)
Prev. Close 2.330
Today's Range 2.260 - 2.380
52wk Range 2.215 - 26.05
Shares Outstanding 736,213
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire

Performance

YTD
-88.8%
-88.8%
1 Month
-19.2%
-19.2%
3 Month
-58.5%
-58.5%
6 Month
-51.2%
-51.2%
1 Year
-87.1%
-87.1%

More News

Read More
Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
From Faruqi & Faruqi LLP
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR
From Pomerantz LLP
Via GlobeNewswire
Law Offices of Howard G. Smith Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
Law Offices of Frank R. Cruz Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
JASPER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Jasper Therapeutics, Inc. (JSPR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
From DJS Law Group
Via Business Wire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged to Contact the Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
From Faruqi & Faruqi, LLP
Via Business Wire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Via Chartmill
Jasper Reports Wider Loss in Fiscal Q2
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Jasper Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Jasper Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Jasper Therapeutics, Inc. - Class A Common Stock trade on?
Jasper Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock is JSPR on the Nasdaq Stock Market
What is the current price of Jasper Therapeutics, Inc. - Class A Common Stock?
The current price of Jasper Therapeutics, Inc. - Class A Common Stock is 2.360
When was Jasper Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Jasper Therapeutics, Inc. - Class A Common Stock was at 09/26/25 10:57 AM ET
What is the market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock is 1.74M
How many shares of Jasper Therapeutics, Inc. - Class A Common Stock are outstanding?
Jasper Therapeutics, Inc. - Class A Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.